Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
Purpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study direc...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=9;spage=1400;epage=1404;aulast=Dudeja |
| _version_ | 1818025592660951040 |
|---|---|
| author | Lakshey Dudeja Anuja Janakiraman Ishani Dudeja Kaustubh Sane Manohar Babu |
| author_facet | Lakshey Dudeja Anuja Janakiraman Ishani Dudeja Kaustubh Sane Manohar Babu |
| author_sort | Lakshey Dudeja |
| collection | DOAJ |
| description | Purpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic conjunctivitis cases. Hence, we decided to methodically study the efficacy of three topical medications. Methods: Prospective, observer-masked clinical trial enrolled 45 patients with 15 patients in each of the three groups. Patients with mild to moderate allergic conjunctivitis were sequentially assigned to respective groups, and relief of symptoms and signs were noted upto 1-month follow-up. Results: All three topical medications faired almost equally in resolving symptoms of the patients with mild to moderate allergic conjunctivitis, and most of them reported complete relief after 1 week of use of medication. Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups. Conclusion: We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis. |
| first_indexed | 2024-12-10T04:18:34Z |
| format | Article |
| id | doaj.art-aacde3a987e24f998f1659b0874917a9 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-12-10T04:18:34Z |
| publishDate | 2019-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-aacde3a987e24f998f1659b0874917a92022-12-22T02:02:30ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892019-01-016791400140410.4103/ijo.IJO_2112_18Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitisLakshey DudejaAnuja JanakiramanIshani DudejaKaustubh SaneManohar BabuPurpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic conjunctivitis cases. Hence, we decided to methodically study the efficacy of three topical medications. Methods: Prospective, observer-masked clinical trial enrolled 45 patients with 15 patients in each of the three groups. Patients with mild to moderate allergic conjunctivitis were sequentially assigned to respective groups, and relief of symptoms and signs were noted upto 1-month follow-up. Results: All three topical medications faired almost equally in resolving symptoms of the patients with mild to moderate allergic conjunctivitis, and most of them reported complete relief after 1 week of use of medication. Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups. Conclusion: We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis.http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=9;spage=1400;epage=1404;aulast=DudejaAlcaftadineallergic conjunctivitisbepotastineolopatadine |
| spellingShingle | Lakshey Dudeja Anuja Janakiraman Ishani Dudeja Kaustubh Sane Manohar Babu Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis Indian Journal of Ophthalmology Alcaftadine allergic conjunctivitis bepotastine olopatadine |
| title | Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis |
| title_full | Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis |
| title_fullStr | Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis |
| title_full_unstemmed | Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis |
| title_short | Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis |
| title_sort | observer masked trial comparing efficacy of topical olopatadine 0 1 bepotastine 1 5 and alcaftadine 0 25 in mild to moderate allergic conjunctivitis |
| topic | Alcaftadine allergic conjunctivitis bepotastine olopatadine |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=9;spage=1400;epage=1404;aulast=Dudeja |
| work_keys_str_mv | AT laksheydudeja observermaskedtrialcomparingefficacyoftopicalolopatadine01bepotastine15andalcaftadine025inmildtomoderateallergicconjunctivitis AT anujajanakiraman observermaskedtrialcomparingefficacyoftopicalolopatadine01bepotastine15andalcaftadine025inmildtomoderateallergicconjunctivitis AT ishanidudeja observermaskedtrialcomparingefficacyoftopicalolopatadine01bepotastine15andalcaftadine025inmildtomoderateallergicconjunctivitis AT kaustubhsane observermaskedtrialcomparingefficacyoftopicalolopatadine01bepotastine15andalcaftadine025inmildtomoderateallergicconjunctivitis AT manoharbabu observermaskedtrialcomparingefficacyoftopicalolopatadine01bepotastine15andalcaftadine025inmildtomoderateallergicconjunctivitis |